Search | Médecins Sans Frontières Access Campaign

2895 results found
There are 0 active filters

2895 results found

MSF staff checking the temperature of Tony, 69, at MSF TB mobile site, Tondo, Manila, Philippines, March 2023

Topic overview

Pandemic prevention, preparedness and response

MSF's positions on pandemic preparedness initiatives, including global pandemic accord

Tags Pandemic preparedness

Different medications a person living with HIV may take every day. Upper-left picture shows a first line treatment. Upper-right is a second-line treatment for patients who do not respond to first-line treatment. Bottom-left is a third-line treatment for patients who do not respond to first- and second-line treatments. Bottom-right is a dolutegravir pill, a new molecule that suppresses viral load much faster than others.

Press release |

04 October 2023

In step to expand people's access to HIV treatment, Colombia plans to overcome patent barriers and issue a compulsory license

Colombia plans to issue compulsory license on HIV drug dolutegravir, expanding access

Tags HIV/AIDSIntellectual property and trade

January 2020 protest in front of the New York Stock Exchange, demanding J&J make bedaquiline more accessible for all people with drug-resistant TB.

Press release |

30 September 2023

MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries

MSF welcomes Johnson & Johnson's intent not to enforce its patents on key TB drug bedaquiline, paving way for affordable generic versions

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson

Vaishnavi, 7, who lives with drug-resistant TB, interacts with MSF nurse Prachi, as her mother Vishaka holds her. Mumbai, India, 2022.

Press release |

22 September 2023

Commitments made in today's UN TB Declaration to scale up TB testing and treatment, and improve TB care for children, require immediate, concrete action

Governments must now turn words on paper into practice and take the necessary steps to save more lives of people with TB

Tags Tuberculosis drug-resistant TBtuberculosis

Fact sheet |

22 September 2023

Tuberculosis: Challenges and Breakthroughs

Despite being curable, why is TB the world’s deadliest infectious disease? What tools do we have to beat the disease?

Tags Tuberculosis drug-resistant TBtuberculosis

Letter |

21 September 2023

Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

The Public Health Center of the Ministry of Ukraine (PHC) sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve equitable access to the lifesaving TB drug bedaquiline in ...

Tags Intellectual property and trade tuberculosis bedaquiline Johnson & Johnson Ukraine

Letter |

21 September 2023

Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Ukraine sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson Ukraine

Letter |

21 September 2023

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Moldova sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Intellectual property and trade tuberculosis bedaquiline Johnson & Johnson Republic of Moldova

Letter |

21 September 2023

Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Civil society organisations, communities affected by tuberculosis (TB), and partner institutions in Azerbaijan sent this open letter to the US pharmaceutical corporation Johnson & Johnson (J&J) requesting urgent action to improve ...

Tags Tuberculosis tuberculosis bedaquiline Johnson & Johnson Azerbaijan

A member of MSF’s mobile vaccination team prepares a dose of COVID vaccine at a nursing home in Shayle, Lebanon, 2021

Statement |

20 September 2023

MSF statement on UN pandemic preparedness meeting and declaration

Future global health emergency responses must be equitable and address people’s needs

Tags Pandemic preparedness

For over 20 years, MSF has provided HIV care in Homa Bay, Kenya, the area with the highest rate of HIV infection in the country. 2020.

Statement |

20 September 2023

MSF reaction statement to UNHLM PPPR declaration

MSF reacts to 2023 UN High-Level Meeting on Pandemic Prevention, Preparedness and Response (PPPR) declaration

Tags Pandemic preparedness

GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Press release |

19 September 2023

TB test price reduction by Cepheid and Danaher is an important step in the right direction

Cepheid and Danaher have just announced that they are reducing the price of the Xpert MTB/RIF test by 20% in high-TB-burden countries, from US$9.98 to $7.97 per test. This reduction is a significant step, considering the corporations ...

Tags Tuberculosis drug-resistant TBtuberculosis GeneXpert Johnson & Johnson

Bottle of bedaquiline, Zhytomyr Regional TB Dispensary, Ukraine. In 2018, MSF started providing treatment for drug-resistant TB to people in Zhytomyr, Ukraine.

Photo credit: Oksana Parafeniuk

Blog |

15 September 2023

The long and winding road to ensure affordable access to a key TB drug

With the United Nations High-Level meeting just over the horizon, the TB community is ready to amplify the voices of people affected by TB around the world at this global forum, and demand the global attention and resources needed to beat this devastating yet curable disease.

Technical brief |

15 September 2023

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

The ongoing PPR negotiations at WHO offer an opportunity to resolve the decades-long tension between IP and access

Tags Pandemic preparednessIntellectual property and trade coronavirus TRIPS WTO

Technical brief |

12 September 2023

“Time for $5” Campaign: Questions and Answers

Q&A on “Time for $5”, a campaign for affordable diagnostic tests

Tags Diagnostics tuberculosis GeneXpert Cepheid Time for $5

Fact sheet |

12 September 2023

Factsheet: “Time for $5” Campaign

The “Time for $5” campaign calls on Cepheid and its parent corporation, Danaher, to prioritise people over profits and reduce the price of GeneXpert tests to $5

Tags Diagnostics tuberculosis GeneXpert Cepheid Time for $5

Video |

12 September 2023

Time for $5 Campaign video

The 'Time for $5' Campaign calls on Cepheid and its parent corporation Danaher to drop the price of GeneXpert tests to $5 a test.

Tags Diagnostics GeneXpert Cepheid Time for $5

Cepheid's price gouging for lifesaving test

Time for $5 graphics

Press release |

12 September 2023

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

MSF calls on J&J and Cepheid/Danaher to commit to improving access to key TB drug and test by UNHLM 22 September

Tags DiagnosticsTuberculosis

Newsletter |

12 September 2023

Join the Time for $5 campaign to save millions of lives

Today we hit the road running with our campaign, ‘Time for $5’, calling on the US company Cepheid, and its parent corporation Danaher, to drop the price of a lifesaving test, GeneXpert, to save millions of people’s lives around the world.

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Pandemic prevention, preparedness and response

In step to expand people's access to HIV treatment, Colombia plans to overcome patent barriers and issue a compulsory license

MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries

Commitments made in today's UN TB Declaration to scale up TB testing and treatment, and improve TB care for children, require immediate, concrete action

Tuberculosis: Challenges and Breakthroughs

Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis

MSF statement on UN pandemic preparedness meeting and declaration

MSF reaction statement to UNHLM PPPR declaration

TB test price reduction by Cepheid and Danaher is an important step in the right direction

The long and winding road to ensure affordable access to a key TB drug

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

“Time for $5” Campaign: Questions and Answers

Factsheet: “Time for $5” Campaign

Time for $5 Campaign video

Time for $5 graphics

Ahead of UN TB High-Level Meeting, US corporations J&J and Cepheid must pledge access to lifesaving TB medicines and tests for everyone in need

Join the Time for $5 campaign to save millions of lives